ImaRx initiates SonoLysis phase II stroke trial

Pharmaceutical developer ImaRx Therapeutics said the first patient has been treated in a new phase II clinical trial evaluating the safety and effectiveness of its SonoLysis product for the treatment of acute ischemic stroke.

SonoLysis combines external ultrasound and ImaRx's proprietary nanobubble technology to clear blood clots. The evaluation is a multicenter randomized and blinded trial with 40 patients, according to the Tucson, AZ-based firm.

By AuntMinnie.com staff writers
April 5, 2005

Related Reading

ImaRx raises $7 million, March 10, 2005

ImaRx, Guerbet in MR molecular imaging deal, December 10, 2004

ImaRx completes private placement, names chairman, April 2, 2004

ImaRx inks licensing deal, November 19, 2003

Clinical trials begin for ImaRx, September 18, 2003

Copyright © 2005 AuntMinnie.com

Page 1 of 512
Next Page